CILIBERTO, DOMENICO
 Distribuzione geografica
Continente #
EU - Europa 127
NA - Nord America 85
AS - Asia 70
SA - Sud America 18
AF - Africa 2
Totale 302
Nazione #
US - Stati Uniti d'America 79
IT - Italia 62
SG - Singapore 53
DE - Germania 35
BR - Brasile 18
FI - Finlandia 13
CA - Canada 5
HK - Hong Kong 5
NL - Olanda 5
GB - Regno Unito 4
TR - Turchia 4
JP - Giappone 3
CZ - Repubblica Ceca 2
RU - Federazione Russa 2
ZA - Sudafrica 2
BD - Bangladesh 1
ES - Italia 1
FR - Francia 1
ID - Indonesia 1
IN - India 1
LB - Libano 1
PK - Pakistan 1
PL - Polonia 1
SE - Svezia 1
TT - Trinidad e Tobago 1
Totale 302
Città #
Singapore 33
Munich 30
Carbonia 12
Turku 12
Chicago 8
Ashburn 7
Santa Clara 7
The Dalles 6
Chandler 5
Hong Kong 5
Rome 5
Ercolano 4
London 4
Naples 3
Nuremberg 3
Tokyo 3
Afragola 2
Boardman 2
Los Angeles 2
Montreal 2
Olomouc 2
Porto Alegre 2
Reggio Calabria 2
San Nicola Manfredi 2
São Paulo 2
West Lafayette 2
Alvorada 1
Amsterdam 1
Ankara 1
Atlanta 1
Augusta 1
Balıkesir 1
Bay City 1
Beirut 1
Benevento 1
Buffalo 1
Caicó 1
Cape Town 1
Chaguanas 1
Charlotte 1
Chennai 1
Cleveland 1
Cosenza 1
Crestview 1
Dallas 1
Ginosa 1
Helsinki 1
Istanbul 1
Itabira 1
Itambaracá 1
Itapemirim 1
Itariri 1
Jaraguá do Sul 1
Johannesburg 1
Lahore 1
Landshut 1
Limeira 1
Manaus 1
Milan 1
New York 1
Norwich 1
Palermo 1
Penápolis 1
Pesqueira 1
Petrópolis 1
Pittsburgh 1
Seattle 1
Siziano 1
Squillace 1
St Petersburg 1
Stockholm 1
Suffern 1
Ubá 1
Warsaw 1
Águas Lindas de Goiás 1
Totale 216
Nome #
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 83
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 44
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 30
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 28
Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity 24
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma 21
LNA-i-miR-221 activity in colorectal cancer: A reverse translational investigation 21
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience 20
First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis 19
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 16
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis 9
Totale 315
Categoria #
all - tutte 2.570
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.570


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/20238 0 0 0 1 0 2 0 2 0 2 1 0
2023/202451 15 2 6 1 1 6 1 0 0 1 12 6
2024/2025215 10 3 0 6 7 32 9 7 14 4 61 62
2025/202641 26 15 0 0 0 0 0 0 0 0 0 0
Totale 315